When was Ray Therapeutics founded?

Ray Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Ray Therapeutics located?

Ray Therapeutics is headquartered in Berkeley, United States.

Who is the current CEO of Ray Therapeutics?

Paul Bresge of Ray Therapeutics. They have also founded 1 company.

How many employees does Ray Therapeutics have?

As of Aug 31, 2026, the latest employee count at Ray Therapeutics is 50.

Is Ray Therapeutics a funded company?

Ray Therapeutics is a funded company, having raised a total of $231M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 04, 2022.

How much is Ray Therapeutics worth?

The latest valuation of Ray Therapeutics is $***** as of Jan 01, 2026.

When was the latest funding round of Ray Therapeutics?

Ray Therapeutics' latest funding was a $***** Grant (prize money) round on Sep 30, 2026, with participation from 1 investor. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.15B in funding in 2026 to date.

Where does Ray Therapeutics rank among its competitors?

Ray Therapeutics ranks 15th amongst 134 active competitors, of which 48 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Ray Therapeutics, which secured $8M in Sep, 2026.

Who are the top competitors of Ray Therapeutics?

Ray Therapeutics' top competitors include Regenxbio, 4D Molecular Therapeutics and Rezolute. Among them, Ray Therapeutics secured the most recent funding round in September, 2026.

Ray Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Ray Therapeutics is a series B company based in Berkeley (United States), founded in 2021 by Paul Bresge. It operates as a Developer of therapeutics for degenerative retinal diseases. Ray Therapeutics has raised $231M in funding from investors like 4Bio Capital, Janus Henderson Investors and Novo Holdings, with a current valuation of $*****. The company has 134 active competitors, including 48 funded and 24 that have exited. Its top competitors include companies like Regenxbio, 4D Molecular Therapeutics and Rezolute.

Company Details

Developer of therapeutics for degenerative retinal diseases. The lead candidate RAY-001 for Retinitis pigmentosa, RAY-002 for geography atrophy, and for other inherited retinal diseases.

Website: raytherapeutics.com
Email ID: *****@raytherapeutics.com

Key Metrics

Founded Year

2021

Location

Berkeley, United States

Stage

Series B

Total Funding

$231M in 7 rounds

Latest Funding Round

Grant (prize money), Sep 30, 2026, $*****

Post Money Valuation

$***** as on Jan 01, 2026

Investors

4Bio Capital & 12 more

Ranked

15^th among 134 active competitors

Employee Count

50 as on Aug 31, 2026

Similar Companies

Regenxbio & 138 more

View Ray Therapeutics' full profile

Ray Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ray Therapeutics, Inc. CIN: 862056423 , United States, Active	Dec 31, 2020	-	16 (As on Dec 31, 2024)	-

Ray Therapeutics has raised a total funding of $231M over 7 rounds. Its first funding round was on Jan 04, 2022. Its latest funding round was a Grant (prize money) round on Sep 30, 2026 for $*****. 1 investor participated in its latest round. Ray Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Ray Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2026	3078192	Grant (prize money)	1656866	5110303	5140646	5487078
Apr 21, 2026	3211972	Series B	7496860	3033470	1702551	Adage Capital Management & 9 more
Apr 24, 2025	8545255	Grant (prize money)	3809391	1928434	9004558	CIRM

Access funding benchmarks and valuations. Sign up today!

View details of Ray Therapeutics's funding rounds and investors

The founders of Ray Therapeutics is Paul Bresge. Paul Bresge is the CEO of Ray Therapeutics.

Here are the details of Ray Therapeutics' key team members:

Paul Bresge: Co-Founder & CEO of Ray Therapeutics.
Contact Info: 1 email address

View details of Ray Therapeutics's Founder profiles and Board Members

Ray Therapeutics' employee count trend

Ray Therapeutics has 50 employees as of Aug 26. Here is Ray Therapeutics's employee count trend over the years:

Employee count trend for Ray Therapeutics

Uncover Ray Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ray Therapeutics include Regenxbio, 4D Molecular Therapeutics and Rezolute. Here is the list of Top 10 competitors of Ray Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	68/100
2nd	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, BVF Partners & 18 others	67/100
3rd	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	66/100
4th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	64/100
5th	Outlook Therapeutics 2011, Cranbury (United States), Public	Developer of antibodies for ophthalmic disorders	$51.8M	Perceptive Advisors, Avoro Capital & 12 others	63/100
6th	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	63/100
7th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Marshall Wace & 10 others	63/100
8th	LENZ Therapeutics 2021, San Diego (United States), Public	Developer of ophthalmic pharmaceutical products	$49M	Sectoral, RTW Investments & 4 others	62/100
9th	Epicrispr Bio 2018, San Francisco (United States), Series C	Developer of therapeutics for multiple disease	$245M	Octagon Capital Advisors, Ally Bridge Group ... & 10 others	62/100
10th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	62/100
15th	Ray Therapeutics 2021, Berkeley (United States), Series B	Developer of therapeutics for degenerative retinal diseases	$231M	Marshall Wace, Janus Henderson Investors ... & 11 others	59/100